Manufacturing of a prothrombin complex concentrate aiming at low thrombogenicity.
The paper describes the production of a prothrombin complex concentrate (PCC) with high virus safety and a well-balanced content of vitamin K-dependent clotting factors and inhibitors. Solid-phase extraction is followed in a second step by optimized anion exchange chromatography using a radial column. A step for virus removal by nanofiltration is introduced in addition to the solvent/detergent step. By speeding up the chromatographic step, the period of time required for production is reduced considerably. The activities of the four vitamin K-dependent clotting factors II, VII, IX and X are in ratios of about 1:1:1:1. Protein C, Protein S, and Protein Z are also present in therapeutically effective concentrations. The product shows no thrombogenicity, in either in vivo nor in vitro models. Clinical investigations show that the PCC is a safe and efficient preparation for the substitutive treatment of FIX or FVII in patients suffering from the respective deficiencies. All bleeding episodes have been efficiently controlled with relatively low doses of the concentrate. The surgical procedures have been conducted without any problems in severely FIX and FVIII deficient patients.
Josić
D
D
Octapharma Pharmazeutika Produktionsges.m.b.H., Oberlaaer Str. 235, A-1100, Vienna, Austria. djuro.josic@octapharma.at
Hoffer
L
L
Buchacher
A
A
Schwinn
H
H
Frenzel
W
W
Biesert
L
L
Klöcking
H P
HP
Hellstern
P
P
Rokicka-Milewska
R
R
Klukowska
A
A
D000818:Animals; D006801:Humans; D011516:Prothrombin / Q000302:isolation & purification* / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D013927:Thrombosis / Q000517:prevention & control
D011516:Prothrombin